The Division of Rheumatology at Cedars-Sinai is a vibrant clinical and academic environment providing cutting-edge diagnosis and treatment for patients affected by autoimmune and inflammatory disorders affecting joints, muscle, skin and bones. We treat conditions such as arthritis, lupus, scleroderma, vasculitis, myositis, gout and other rheumatic diseases.
We offer a multidisciplinary team of experts, including rheumatologists, nurses, physical and occupational therapists, dieticians, social workers, research scientists and other health professionals who strive to deliver outstanding, compassionate, state-of-the-art care. Team members collaborate to diagnose and effectively treat and monitor these rheumatic conditions, working with each patient to develop an individualized treatment program.
Cedars-Sinai attracts world-renowned research scientists investigating the causes of these autoimmune disorders to predict clinical outcomes with greater precision and ultimately discover safer and more effective therapies. Patients with rheumatic conditions have an opportunity to participate in clinical trials that are designed to test the effectiveness of the most promising new treatments.
Kao Autoimmunity Institute and Scleroderma Program
The Kao Autoimmunity Institute and Scleroderma Program are dedicated to advancing the research, diagnosis and treatment of autoimmune diseases.
The Rheumatology Division promotes innovative clinical and translational research. Our goal is to discover key components of susceptibility to rheumatic disorders, identify dominant pathogenetic mechanisms and pursue novel treatment opportunities.
The Rheumatology Fellowship at Cedars-Sinai provides a diverse experience tailored to the career goals of each trainee. We prepare fellows to become knowledgeable and disciplined practitioners in rheumatic diseases, as well as critical thinkers, researchers and educators.
Learn more about our wide range of clinical trials aimed at making new treatments available for patients living with rheumatic diseases.